Zimmer Biomet Holdings, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Zimmer Biomet Holdings, Inc. on April 21, 2025. The report details the completion of a previously announced acquisition. On this date, the Company's subsidiary, Merger Sub, merged with and into Paragon 28, Inc., with Paragon 28 continuing as a wholly owned subsidiary of Zimmer, Inc.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The primary financial disclosure relates to the transaction consideration paid to Paragon 28 shareholders:
- Cash Consideration: $13.00 per share of Paragon 28 common stock.
- Contingent Consideration: One contractual contingent value right (CVR) per share.
Material Changes
The material change reported is the closing of the Merger Agreement entered into on January 28, 2025. As of the Effective Time on April 21, 2025, Paragon 28 became a wholly owned subsidiary of the Company. Outstanding shares of Paragon 28 were converted into the right to receive the cash and CVR consideration described above, excluding shares owned by the Company or its subsidiaries and shares subject to appraisal rights.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors beyond the standard disclosure of the transaction closing. The transaction involves contingent value rights, which represent a future financial obligation dependent on specific performance metrics defined in the Contingent Value Rights Agreement.
Investor Verification Checklist
- Verify the terms and performance triggers of the Contingent Value Rights Agreement to understand potential future cash outflows.
- Review the press release filed as Exhibit 99.1 for additional details on the strategic rationale and integration plans.
- Confirm the number of Paragon 28 shares outstanding to calculate the total cash consideration paid.
- Monitor subsequent filings for the impact of this acquisition on the Company's consolidated balance sheet and debt covenants.